- Home
- VCYT vs IDYA Comparison
VCYT vs IDYA Comparison
Compare VCYT & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCYT
- IDYA
- Stock Information
- Founded
- VCYT 2006
- IDYA 2015
- Country
- VCYT United States
- IDYA United States
- Employees
- VCYT 824
- IDYA 131
- Industry
- VCYT Medical Specialities
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- VCYT Health Care
- IDYA Health Care
- Exchange
- VCYT Nasdaq
- IDYA Nasdaq
- Market Cap
- VCYT 2.4B
- IDYA 2.1B
- IPO Year
- VCYT 2013
- IDYA 2019
- Fundamental
- Price
- VCYT $30.22
- IDYA $24.33
- Analyst Decision
- VCYT Buy
- IDYA Strong Buy
- Analyst Count
- VCYT 9
- IDYA 13
- Target Price
- VCYT $39.89
- IDYA $51.36
- AVG Volume (30 Days)
- VCYT 2.4M
- IDYA 1.1M
- Earning Date
- VCYT 08-06-2025
- IDYA 08-05-2025
- Dividend Yield
- VCYT N/A
- IDYA N/A
- EPS Growth
- VCYT N/A
- IDYA N/A
- EPS
- VCYT 0.34
- IDYA N/A
- Revenue
- VCYT $479,129,000.00
- IDYA $7,000,000.00
- Revenue This Year
- VCYT $12.57
- IDYA $101.44
- Revenue Next Year
- VCYT $10.23
- IDYA $263.37
- P/E Ratio
- VCYT $90.02
- IDYA N/A
- Revenue Growth
- VCYT 19.91
- IDYA N/A
- 52 Week Low
- VCYT $22.61
- IDYA $13.45
- 52 Week High
- VCYT $47.32
- IDYA $40.74
- Technical
- Relative Strength Index (RSI)
- VCYT 67.14
- IDYA 56.51
- Support Level
- VCYT $26.61
- IDYA $22.09
- Resistance Level
- VCYT $30.73
- IDYA $24.75
- Average True Range (ATR)
- VCYT 1.17
- IDYA 1.23
- MACD
- VCYT 0.75
- IDYA -0.06
- Stochastic Oscillator
- VCYT 93.47
- IDYA 55.04
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.